Can CVS Sustain Pharmacy & Consumer Wellness Gains Through Year-End?

CVS Health's Pharmacy and Consumer Wellness (PCW) segment reported an 11.1% revenue increase in Q1 2025, driven by strong vaccine demand, a prolonged flu season, and rising GLP-1 medication sales, notably via its expanded NovoCare network access for Wegovy. The implementation of its CostVantage reimbursement model and a robust 27.6% retail pharmacy script share, despite its 900-store closure plan, are poised to support continued growth, although ongoing reimbursement pressure and evolving consumer sentiment pose potential headwinds. CVS shares have outperformed, rallying 18.9% over the past year and trading at a discounted 10.18x forward P/E, suggesting investor confidence despite challenges.

Analysis

CVS Health's Pharmacy and Consumer Wellness (PCW) segment demonstrated robust performance in the first quarter of 2025, with revenues climbing 11.1% year-over-year. This growth was fueled by seasonal factors, such as a prolonged flu season and high vaccine demand, as well as structural tailwinds including the rising popularity of GLP-1 medications. The company has strategically positioned itself to capitalize on this trend by joining Novo Nordisk's NovoCare network, which expands access to Wegovy across its 9,000 locations. Furthermore, the full implementation of its CostVantage reimbursement model is expected to bolster operating income by creating a more transparent pricing system for commercial prescriptions. Despite completing a 900-store closure plan, CVS successfully grew its retail pharmacy script share by nearly 70 basis points to 27.6%, indicating strong operational execution and market consolidation. While the stock has outperformed the industry with an 18.9% gain over the past year against the sector's 14.6% decline, it trades at a discounted forward P/E multiple of 10.18x versus the industry average of 14.07x. However, persistent pharmacy reimbursement pressure and potential headwinds from a softening consumer environment remain key risks to monitor.

Key Decisions for Investors

• Given the combination of strong revenue growth, strategic positioning in the high-demand GLP-1 market, and a discounted forward P/E of 10.18x, investors may see a favorable value and growth opportunity.
• Monitor future earnings reports to verify that the new CostVantage model and increased market share can sustain momentum as the tailwinds from seasonal factors like the flu and vaccine cycle diminish.
• Closely track management commentary on pharmacy reimbursement pressures and the broader consumer environment, as these are cited as the primary headwinds to the segment's growth outlook.
• Evaluate CVS's market share performance in the context of strong competitive results, such as Walmart's high-teens growth in health and wellness, to gauge the durability of its market position.